RBC Life Sciences, Inc.
RBCL
$0.0001
$0.000.00%
| 09/30/2015 | 06/30/2015 | 03/31/2015 | 12/31/2014 | 09/30/2014 | |
|---|---|---|---|---|---|
| Revenue | -12.49% | -1.72% | 9.51% | 10.99% | 10.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -12.49% | -1.72% | 9.51% | 10.99% | 10.88% |
| Cost of Revenue | -19.68% | -14.79% | -6.48% | -6.14% | 0.32% |
| Gross Profit | -6.13% | 11.29% | 26.88% | 30.19% | 22.27% |
| SG&A Expenses | 4.22% | 13.38% | 23.66% | 29.67% | 23.20% |
| Depreciation & Amortization | -11.14% | 1.03% | 2.10% | 5.57% | 3.90% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -6.96% | -0.44% | 8.24% | 10.73% | 11.25% |
| Operating Income | -172.78% | -37.29% | 20.23% | -0.08% | -24.99% |
| Income Before Tax | 29.15% | -31.83% | 19.77% | 2.05% | -19.43% |
| Income Tax Expenses | 52.83% | -13.40% | 40.13% | 50.00% | -9.82% |
| Earnings from Continuing Operations | 21.22% | -38.95% | 10.97% | -20.52% | -23.02% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.22% | -38.95% | 10.97% | -20.52% | -23.02% |
| EBIT | -172.78% | -37.29% | 20.23% | -0.08% | -24.99% |
| EBITDA | -615.07% | -114.28% | 36.30% | -24.73% | -208.23% |
| EPS Basic | 21.21% | -39.05% | 10.84% | -20.79% | -23.46% |
| Normalized Basic EPS | -150.84% | -31.92% | 19.68% | 1.93% | -19.87% |
| EPS Diluted | 23.86% | -37.02% | 12.26% | -16.12% | -26.66% |
| Normalized Diluted EPS | -150.84% | -31.92% | 19.68% | 1.93% | -19.87% |
| Average Basic Shares Outstanding | 0.00% | -0.05% | -0.17% | -0.29% | -0.41% |
| Average Diluted Shares Outstanding | 0.00% | -0.05% | -0.17% | -0.29% | -0.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
